Senator Warren Urges FTC to Scrutinize Novo Nordisk's $16.5 Billion Catalent ($CTLT) Deal

Oct 10, 2024, 04:05 PM

US Senator Elizabeth Warren has called for regulators to closely scrutinize a $16.5 billion deal in which Novo Nordisk's parent foundation would acquire Catalent ($CTLT), a contract drug manufacturer. Warren urged the Federal Trade Commission (FTC) to investigate whether the deal would give Novo Nordisk ($NVO) an unfair advantage in the market for obesity and diabetes drugs. She expressed concerns about the potential control Novo Nordisk would gain over some of Catalent's plants.